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TBackground: It has been previously shown that a persistent (up to 1 month)
prothrombotic status occurs after coronary bypass surgery performed both on pump
and off pump. To assess the pathways involved in the occurrence of postoperative
prothrombotic state, in this study we evaluated plasma, monocyte-bound, and
platelet-bound tissue factor expression, as well as platelet and soluble P-selectin
expression, up to 1 month after off-pump and on-pump coronary artery bypass
grafting.
Methods: Thirty patient candidates for coronary surgery were randomized to un-
dergo off-pump coronary artery bypass grafting (n  15) or on-pump coronary
artery bypass grafting (n 15). Blood samples were collected before the intervention,
after protamine administration, and 4, 8, and 30 days after surgical intervention.
Results: Plasma tissue factor levels were significantly higher than baseline both in
the on-pump coronary artery bypass grafting group (from protamine administration
up to 4 postoperative days) and in the off-pump coronary artery bypass grafting
group (at 4 postoperative days), with no differences between groups. Basal and
lipopolysaccharide-stimulated monocyte tissue factor expression, as well as basal
and adenosine diphosphate–stimulated platelet tissue factor expression, did not
show significant variations over time and were similar in the on-pump and off-pump
coronary artery bypass grafting groups throughout the course of the study. Platelet
expression of P-selectin, both basal and after adenosine diphosphate stimulation, did
not significantly change over time and was not different in the on-pump and
off-pump coronary artery bypass grafting groups. Soluble P-selectin levels in
plasma were significantly higher in patients receiving on-pump coronary artery
bypass grafting only at the time point after protamine administration, whereas this
variable behaved similarly in the on-pump and off-pump coronary artery bypass
grafting groups for the whole postoperative period.
Conclusions: The postoperative tissue factor and P-selectin expression did not differ
between the on-pump and off-pump coronary artery bypass grafting groups. The
distinct increase of plasma tissue factor occurring after both surgical procedures
might represent a mechanism that might explain, in part, the early postoperative
prothrombotic state occurring after on-pump and off-pump coronary artery bypass
grafting.
It has been previously shown that a sensible activation of the hemostatic-thrombotic and inflammatory systems occurs during the intervention and per-sists for several weeks after coronary artery bypass surgery.1-4 This activation is
more marked in patients undergoing on-pump coronary artery bypass grafting
(CABG), which lasts for the limited time span during the operation and in the very
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CSPearly hours thereafter, compared with that seen in patients
submitted to off-pump coronary artery bypass grafting (OP-
CAB). At later times (eg, after the first postoperative hours
up to 1 month after the operation), the degree of this
activation is similar in patients undergoing both CABG and
OPCAB.5
Both tissue factor (TF) pathways6-8 and platelet activa-
tion9 have been previously documented as mechanisms un-
derlying the early hemostatic activation phase occurring
during and in the early hours after coronary surgery. It is
unclear, however, which pathway is involved in the occur-
rence and development of the late phases of this prothrom-
botic state that, unlike the early activation phase, seems to
be unrelated to extracorporeal circulation use.5
In this study we have investigated whether TF and
P-selectin play a role in the delayed activation of coagula-
tion occurring after coronary surgery.
Patients and Methods
Patients
Thirty patient candidates for elective surgical myocardial revascu-
larization according to the American Heart Association/American
College of Cardiology guidelines10 and in whom both OPCAB and
CABG were considered feasible were enrolled during the time
period from July 2003 through December 2003 and randomized to
undergo OPCAB (n  15) or CABG (n  15). In all cases the
preoperative ejection fraction was greater than 30%, and the left
ventricular end-diastolic pressure was less than 20 mm Hg. Pre-
operative exclusion criteria were age of 80 years or older, renal or
liver disease, intake of drugs affecting platelet function or coagu-
lation, or fibrinolysis within 10 days before the operation, whereas
intraoperative and postoperative exclusion criteria were excessive
(1000 mL/24 hours) postoperative bleeding or re-exploration for
bleeding, perioperative myocardial infarction, stroke, or renal fail-
ure requiring dialysis. Clinical variables of patients undergoing
CABG and OPCAB are reported in Table E1 (electronic pages).
All patients provided informed consent to participate in this
study, which was approved by the Institutional Review Board of
Centro Cardiologico Monzino IRCCS. All patients were managed
Abbreviations and Acronyms
ADP  adenosine diphosphate
ANOVA analysis of variance
CABG  on-pump coronary artery bypass grafting
FITC  fluorescein isothiocyanate
GLM  general linear model
mAb monoclonal antibody
MFI mean fluorescence intensity
OPCAB off-pump coronary artery bypass grafting
PE  phycoerythrin
TF  tissue factor
WB  whole bloodby the same surgical and anesthesiologic team.
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Patient management during and after the operation was the same in
both groups of patients. All patients continued their cardiac med-
ications until the operation.
Patients received thiopentone, 3 to 5 mg/kg, and fentanyl,
1 g/kg, as induction and were maintained with sufentanil boluses
of up to 4 to 5 g/kg associated with propofol (Diprivan, Astra-
Zeneca) continuous infusion at 3 mg · kg1 · h1.
After orotracheal intubation, patients were ventilated with oxygen
and air (fraction of inspired oxygen, 50%), maintaining PaCO2 at
between 35 and 38 mm Hg. Rectal and cervical esophageal probes
were used for temperature monitoring, and acid-base equilibrium
was maintained by using the alpha-stat method.
After internal thoracic artery takedown, systemic hepariniza-
tion (300 IU/kg bovine lung heparin) was given in both groups,
and anticoagulation was assessed with celite ACT, with a trigger
level for additional heparin set at 440 seconds every 30 minutes
during cardiopulmonary bypass (CPB; in the CABG group) or
during coronary anastomosis confection (in the OPCAB group).
On completion of distal and proximal coronary anastomoses,
heparin was antagonized with protamine sulfate at a 1:1 ratio
(3 mg/kg) in both groups. The protamine dose was based on total
heparin used during the operation.
CABG Surgery
A nonpulsatile roller pump, hollow-fiber oxygenator with inte-
grated heat exchanger, arterial filter, open cardiotomy reservoir,
and polyvinyl tubing system were used in all cases. Each operation
was performed with tepid hypothermia (32°C-34°C) and hemodi-
lution. Blood flow during CPB was kept at 2.4 L · min1 · m2,
and hematocrit was kept at 18% to 25%. Myocardial protection
was achieved through the administration of cold (4°C) multidose
blood cardioplegia infused through the aortic root and the coronary
sinus.
OPCAB Surgery
All OPCAB surgeries were performed through a midline sternot-
omy; mechanical stability of the coronary arteriotomy area was
achieved with a suction stabilizer, and a soft plastic coronary flow
shunt was always introduced into the coronary arteriotomy to
maintain some degree of distal flow, to reduce myocardial isch-
emia, and to improve visualization of the anastomosis area. Cor-
onary artery exposure was achieved with stay sutures applied on
the left lateral side of the pericardium or with deep pericardial stay
sutures placed above the entry to the left lower pulmonary vein and
laterally to the entry of the inferior vena cava (Lima stitch).
Follow-up
All the patients were hospitalized until the 8th postoperative day.
Then all patients underwent a follow-up visit (physical examina-
tion, electrocardiograph, and blood collection) at the 30th postop-
erative day.
Blood Sampling
Blood collection was performed from the antecubital vein through
a 19-gauge needle without venous stasis. After discarding the first
4 mL, blood was drawn into citrate-containing (1:10 vol sodium
citrate 0.129 mol/L) Vacutainer tubes (Becton Dickinson) at base-
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Pline (the day before the operation), 5 minutes after protamine
administration, at stable hemodynamic conditions, and at 4, 8, and
30 days after surgical intervention. Plasma was prepared by means
of centrifugation at 1500g for 20 minutes at 4°C within 30 minutes
from venipuncture, divided into aliquots, and frozen at 80°C
until assayed.
For laboratory methods please see the Electronic Appendix.
Statistical Analysis
The study was powered to detect, with a power of 80%, an  error
of .05, a percentage change from baseline equal to 1 standard
deviation in any time point. Continuous variables are presented
as means  1 standard error of the mean, and categoric vari-
ables are presented as percentages. Group differences in clinical
variables between the CABG and OPCAB groups were assessed
with analysis of variance (ANOVA) and 2 or Fisher exact tests
when indicated.
General linear model (GLM) ANOVA models were used for
statistical analysis of time, group (CABG vs OPCAB), and
interaction (time * group) effects (main effects) in hematologic
variables assessed as percentage variations from baseline val-
ues. When time, group, or interaction effects were significant (P 
.05), repeated-measures ANOVA with the Bonferroni correction
was used to determine significant (P  .05) point-by-point
differences.
Results
Absolute values of tissue factor and p-selection are reported
in the electronic pages (Table E2).
Tissue Factor
Plasma TF. Baseline plasma TF levels were similar in
the CABG and OPCAB groups (157  5.5 and 145  6.2
pg/mL, respectively). GLM ANOVA showed a significant
effect of time (P  .045) but not of treatment (P  .57);
point-by-point analysis documented significant increases
with respect to the baseline occurring both in the CABG
group (after protamine: 72%  20%, P  .02; 4 days
postoperatively: 83%  26%, P  .03) and the OPCAB
group (4 days postoperatively: 98%  33%, P  .05;
Figure 1, A).
Monocyte TF expression. Basal and lipopolysaccha-
ride-stimulated monocyte TF expression was similar in the
CABG and OPCAB groups before the operation (basal:
0.95  0.043 and 0.95  0.037 mean fluorescence intensity
[MFI], respectively; stimulated: 1.59  0.094 and 1.46 
0.115 MFI, respectively) and did not change in either group
throughout the course of the study (Figure 1, B and C).
Platelet TF expression. Unstimulated and stimulated
platelet TF expression was similar in the CABG and
OPCAB groups before the operation (unstimulated: 2.15 
0.208 and 1.83  0.150 MFI, respectively; stimulated:
3.37  0.182 and 3.15  0.230 MFI, respectively). The
analysis of TF expression in unstimulated platelets showed
a significant effect of time (P  .018); point-by-point anal-
The Journal of Thoracicysis, however, did not show any significant difference with
respect to baseline in both groups (Figure 1, D). Adenosine
diphosphate (ADP)–induced platelet TF expression did not
change throughout the study in either the CABG or OPCAB
group (Figure 1, E).
P-selectin
Platelet P-selectin expression. Unstimulated and stimu-
lated platelet P-selectin expression was similar in the CABG
and OPCAB groups before the operation (unstimulated:
0.94  0.019 and 0.90  0.035 MFI, respectively; stimu-
lated: 3.97  0.496 and 2.67  0.416 MFI, respectively).
Both unstimulated and stimulated P-selectin expression did
not show significant variations over time or differences
between patients assigned to the CABG and OPCAB groups
(Figure 2, A and B).
Soluble P-selectin. Soluble P-selectin levels were simi-
lar at baseline in the CABG and OPCAB groups (101 3.7
and 93  3.0 ng/mL, respectively). GLM ANOVA showed
a significant effect of time (P .001), treatment (P .036),
and interaction (P  .013) terms; point-by-point analysis
showed no differences over time in the OPCAB group,
whereas in the CABG group there was a significant increase
with respect to baseline after protamine administration
(41%  10%, P  .05). At this time point, there was also
a significant difference between the CABG and OPCAB
groups (41%  10% and 23%  10%, respectively;
P .001), whereas no differences could be demonstrated in
the postoperative period both with respect to baseline and
between the CABG and OPCAB groups (Figure 2, C).
Discussion
Several studies have documented major changes in hemo-
static variables occurring during and early after CABG
performed with the use of CPB. Activation of the extrinsic
coagulation pathway occurs during surgical intervention
and is due to blood that first comes into contact with
nonendothelial surfaces of the pump and especially of the
surgical wound and then is directed to the pump; this is an
important trigger for intraoperative coagulation activation
because it is followed by early and sharp increases of
thrombin generation markers.7,8 Likewise, sensible platelet
activation has been documented to occur during and in the
early phases after coronary surgery, being characterized by
increased platelet expression of P-selectin and also in-
creased levels of its soluble form.9
The above-mentioned evidence comes, however, from stud-
ies that were focused on the very early phase after surgical
intervention, extending observation times for a maximum of 24
to 48 hours after CABG. A protracted prothrombotic state
occurring after CABG was recently demonstrated,1 even
though the mechanisms underlying this state have not been
investigated yet. Moreover, a sensible activation of hemo-
and Cardiovascular Surgery ● Volume 130, Number 6 1563
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surgery performed off pump; this activation is of relatively
Figure 1. Tissue factor (TF). Plasma tissue factor (A),
stimulated monocyte tissue factor (C), baseline plate
stimulated platelet tissue factor (E) are shown at each
error of the mean. Open circles indicate patients assi
 15), and filled squares indicate patients assigned to
*P  .02, **P  .05, ***P  .03 versus baseline. GLMlower degree in off-pump coronary surgery during and in
1564 The Journal of Thoracic and Cardiovascular Surgery ● Decthe very early hours thereafter,5,11 whereas at later times,
the extent of this activation is similar between on-pump and
eline monocyte tissue factor (B), lipopolysaccharide-
issue factor (D), and adenosine diphosphate (ADP)–
interval. Data are presented as means  1 standard
to on-pump coronary artery bypass grafting (CABG; n
ump coronary artery bypass grafting (OPCAB; n  15).
VA, General linear model analysis of variance.bas
let t
time
gned
off-p
ANOoff-pump procedures5; this led to the hypothesis that extra-
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Pcorporeal circulation is the cause of the perturbations oc-
curring early after surgical intervention, whereas surgical
Figure 2. P-selectin. Baseline platelet P-selectin (A), adenosine
diphosphate (ADP)–stimulated platelet P-selectin (B), and soluble
P-selectin (C) expression are shown at each time interval. Data
are presented as means  1 standard error of the mean. Symbols
are as in Figure 1. *P  .002 vs baseline and **P < .001, on-pump
coronary artery bypass grafting (CABG) versus off-pump coronary
artery bypass grafting (OPCAB). GLM ANOVA, General linear
model analysis of variance.trauma is likely to be responsible for the later ones.12
The Journal of ThoracicOur study shows that the delayed activation of the coag-
ulation that occurs after coronary bypass surgery is not
caused by platelet activation. Indeed, established markers of
platelet activation, platelet-bound P-selectin expression,7
soluble P-selectin,9 and a possibly new indicator of platelet
activation, platelet-bound TF,13 did not show sensible
changes in the postoperative period up to 1 month.
In addition, the parallel in vivo behavior of basal and
ADP-stimulated platelet expression of P-selectin, which not
only mediates the adherence of platelets to leukocytes and
endothelial cells but also enhances the expression of TF on
monocytes,14 and of platelet-bound TF further rules out a
possible role of platelet activation in the postoperative pe-
riod. This observation confirms and extends previous find-
ings documenting similar behavior of these 2 differently
located markers of platelet activation after ADP stimulus in
vitro in healthy subjects.13
Particular attention should be given to TF, one of the
main contributors of the early postsurgical hemostatic acti-
vation phase, a major determinant of atherosclerotic plaque
thrombogenicity,15 and the most likely mechanism of early
saphenous vein graft failure caused by graft thrombosis.16
Interestingly, cell-associated TF did not sensibly change in
the perioperative period. Four days after the operation,
however, TF circulating in plasma significantly increased,
in accordance with previous findings from our group doc-
umenting a trend toward increased levels of this variable
occurring a few days after CABG.1,5 Circulating TF antigen
is detectable in blood from healthy subjects, and increased
levels of this protein are found in patients with cardiovas-
cular disease, sepsis, and hematologic and coagulation dis-
orders.17 It recognizes several different cellular sources (eg,
disrupted atherosclerotic plaques, platelets, apoptotic leuko-
cytes, and endothelial cells), can circulate freely in the
blood or in the form of cell-derived microparticles, and
might contribute to thrombus propagation,17-19 even though,
depending on clinical situations, it might or might not bear
procoagulant properties.19
The increase in soluble TF levels, which is common to
CABG and OPCAB, might at least in part explain the
increase in thrombin generation markers previously de-
scribed from our group that occurs in the postoperative
period of both CABG1,2,5 and OPCAB5 operations and that
lasts up to 30 days after the operation. A possible explanation
for the less protracted increase in TF with respect to thrombin
generation markers is that TF activity of blood might need to
be rapidly modulated and confined outside of the flowing
blood or inside of the cells in contact with it to avoid excessive
coagulation activation. In fact, it has been previously de-
scribed that sensible amounts of TF might exist in an
encrypted nonfunctional form on microparticles,20 which
are a heterogeneous family of small membrane vesicles
released from different cells (eg, endothelial cells, mono-
and Cardiovascular Surgery ● Volume 130, Number 6 1565
Cardiopulmonary Support and Physiology Parolari et al
CSPcytes, granulocytes, and platelets) on activation or during
apoptosis and act as transcellular effectors showing, on
certain conditions, highly procoagulant features.21,22
Finally, no differences were detected between on-pump
and off-pump operations in all the markers studied, with the
exception of intraoperative higher levels of soluble P-selec-
tin in patients in the CABG group, with the postoperative
behavior of this marker being very similar in both groups.
This adds further support to the hypothesis that, after an
early phase of coagulation activation, where differences in
some hemostatic variables do occur, CABG and OPCAB
show a very similar pattern of biologic pathways activation
not related to CPB and probably caused by the surgical
trauma common to both procedures.5
In conclusion, cell-associated TF and P-selectin do not
contribute to the postoperative procoagulant response that
occurs in the first month after coronary bypass surgery
performed both on pump and off pump, whereas the post-
operative increase of plasma TF levels is the common
mechanism that might in part explain the postoperative
prothrombotic state occurring in low-risk patients undergo-
ing uneventful CABG and OPCAB. It is possible, however,
that different scenarios might occur in patients with impor-
tant thrombotic or bleeding complications.
There is the need for future studies addressing the be-
havior of hemostatic variables in patients with thrombotic or
hemorrhagic postoperative complications.
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Materials
Adenosine diphosphate (ADP) and Escherichia coli lipopolysac-
charide were from Sigma. Fluorescein isothiocyanate (FITC)–
labeled monoclonal antibody (mAb) anti-human TF was from
American Diagnostica. FITC-conjugated anti-human P-selectin
mAb and phycoerythrin (PE)-conjugated anti-human glycoprotein
IIb/IIIa mAb (CD41) were from Instrumentation Laboratories.
PE-conjugated anti-human CD14 and FITC- and PE-labeled IgG1
isoantibodies were from Becton Dickinson.
Platelet Analysis by Means of Flow Cytometry
Platelet-associated TF and P-selectin expression were determined
in whole blood (WB) by means of flow cytometry. Levels of the
proteins were assessed both under resting conditions and on stim-
ulation with ADP. Briefly, immediately after collection, 5 L of
blood was stimulated for 15 minutes at room temperature with
ADP (10 mol/L, stimulated sample) or vehicle (control sample)
without stirring. Then samples were incubated for 15 minutes with
saturating concentrations of the specific FITC- or PE-conjugated
antibodies and analyzed with a flow cytometer (FACSCalibur,
Becton Dickinson) equipped with a 15-mW, air-cooled, 488-nm
argon-ion laser. Leukocytes were excluded with a combination of
size- and platelet-specific marker (CD41) gating. The FITC-posi-
tive events (TF and P-selectin) were determined in 10,000 CD41
platelets per sample. Isotype control mAbs were used in each
experiment to determine nonspecific background mAb binding.
Mean FITC fluorescence intensity was calculated from fluores-
cence histograms for the gated population, and data were analyzed
The Journal of Thoracic anwith a computer (CELLQuest software, Becton Dickinson). The
results are expressed as the percentage change from baseline
(Figures 1 and 2) and as mean fluorescence intensity (MFI; Table
E2).
Monocyte Analysis by Means of Flow Cytometry
For flow cytometric determination of monocyte TF expression,
500 L of unstimulated WB and 500 L of WB stimulated with
lipopolysaccharide (10 ng/mL) were incubated for 5 hours at 37°C
without stirring. Then samples were fixed with 1% formaldehyde
for 30 minutes at 4°C and washed twice. The fixed samples were
incubated for 30 minutes with saturating concentrations of PE-
labeled anti-CD14 and FITC-labeled anti-TF and then resuspended
in 700 L of lysis buffer and analyzed by means of flow cytom-
etry. The TF-positive events were determined in 3000 CD14
monocytes per sample. Isotype control mAbs were used in each
experiment to determine nonspecific background mAb binding.
Mean FITC fluorescence intensity was calculated from florescence
histograms for the gated population, and data were analyzed with
a computer (CELLQuest software, Becton Dickinson). The results
are expressed as percentage change from baseline (Figures 1 and
2) and as MFI (Table E2).
Plasma TF and P-selectin
Plasma TF and P-selectin levels were determined by means of
enzyme-linked immunosorbent assay (ELISA; American Diagnos-
tica and R&D Systems, respectively), according to the manufac-
turer’s instructions.
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CSPTABLE E1. Clinical variables in the study population
Variable CABG (n  15) OPCAB (n  15) P value
Age (y) 64  1.4 65 1.2 .58
Male sex (%) 10 (67%) 9 (60%) .99
Previous MI (%) 9 (60%) 6 (40%) .47
Type I diabetes (%) 1 (7%) 2 (13%) .99
Type II diabetes (%) 3 (20%) 3 (20%) .99
COPD (%) 2 (13%) 4 (27%) .65
Hypertension (%) 13 (87%) 10 (67%) .39
Echocardiographic EF (%) 56 1.5 58  1.8 .39
Preoperative hematocrit (%) 39 0.9 38  1.2 .53
Diseased coronary vessels 2.9 0.16 2.8  0.13 .63
Distal anastomoses 3.2 9.29 2.8  0.23 .27
CPB time (min) 108 5.5 – –
Crossclamp time (min) 83 3.7 – –
2-h bleeding (mL) 97 8.3 86  6.4 .29
24-h bleeding (mL) 450 21 467 23 .58
Total bleeding (mL) 601 15 639 18 .11
Ventilation time (h) 6.4 1.34 5.4  1.61 .08
CABG, On-pump coronary artery bypass grafting; OPCAB, off-pump coronary artery bypass grafting; MI, myocardial infarction; COPD, chronic obstructive
pulmonary disease; EF, ejection fraction; CPB, cardiopulmonary bypass.
TABLE E2. Tissue factor and P-selectin levels before, during, and after the operation in the CABG and OPCAB groups
Baseline Protamine 4 d 8 d 30 d
Plasma tissue factor (pg/mL) CABG 157 5.5 233 7.3 275 12.9 217 5.5 157  5.6
OPCAB 145 6.2 169 3.9 263 16.5 145 5.5 150  4.8
Unstimulated monocyte tissue
factor expression (MFI)
CABG 0.95  0.043 1.00 0.040 0.93 0.032 1.01 0.043 0.93 0.048
OPCAB 0.95 0.037 0.89 0.029 0.93 0.039 0.99 0.043 0.87 0.021
Stimulated monocyte tissue
factor expression (MFI)
CABG 1.59  0.094 1.76 0.136 1.41 0.080 1.54 0.115 1.51 0.061
OPCAB 1.46 0.115 1.25 0.067 1.43 0.107 1.57 0.152 1.38 0.048
Platelet tissue factor expression
(MFI)
CABG 2.15  0.208 1.76 0.126 2.40 0.246 2.20 0.192 1.92 0.147
OPCAB 1.83 0.150 1.67 0.110 1.75 0.152 1.78 0.139 1.62 0.166
ADP-induced platelet tissue
factor expression (MFI)
CABG 3.37  0.182 2.85 0.139 3.53 0.251 3.22 0.190 2.68 0.083
OPCAB 3.15 0.230 2.82 0.203 2.63 0.190 2.68 0.142 2.61 0.166
Platelet P-selectin expression
(MFI)
CABG 0.94  0.019 0.90 0.027 0.97 0.024 0.89 0.024 1.03 0.067
OPCAB 0.90 0.035 0.89 0.037 0.86 0.013 0.90 0.021 0.98 0.032
ADP-induced platelet P-selectin
expression (MFI)
CABG 3.97  0.496 3.04 0.283 4.32 0.267 4.01 0.323 3.84 0.393
OPCAB 2.67 0.416 2.32 0.179 2.44 0.182 2.60 0.198 3.16 0.390
Soluble P-selectin (ng/mL) CABG 101 3.7 131 3.4 111 3.5 133 3.1 107  2.5
OPCAB 93 3.0 64 1.3 97 2.4 113 4.4 93 2.1
CABG, On-pump coronary artery bypass grafting; OPCAB, off-pump coronary artery bypass grafting; MFI, mean fluorescence intensity; ADP, adenosine
diphosphate.
1566.e2 The Journal of Thoracic and Cardiovascular Surgery ● December 2005
